Anlon Healthcare Share Price: Stock Market Debut Sees Muted Start

Market Performance

The stock market today saw the debut of Anlon Healthcare, a pharmaceutical company that recently concluded its IPO. On September 3, the company made its first appearance on the bourses with a mixed listing.

• On the NSE, shares listed at ₹92 per share, marking a modest 1% premium over the IPO issue price of ₹91.
• On the BSE, the stock opened flat at ₹91 per share, showing no premium at listing.
• At debut, Anlon Healthcare’s market capitalization stood at ₹485 crore, as per BSE data.

This subdued listing stood in line with market expectations and kept investor sentiment cautious around the newly-listed stock.

Main News: IPO Subscription and Fundraising

Anlon Healthcare’s IPO had witnessed strong demand during the bidding window. The issue was subscribed more than 7 times over its offer size, reflecting healthy participation from investors across categories.

The company successfully raised over ₹121 crore through a fresh issue of 1.33 crore equity shares, priced in the band of ₹86–₹91 per share.

Company Details

Anlon Healthcare is engaged in the pharmaceutical industry, focusing on the manufacturing of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company has been steadily expanding its product offerings to cater to both domestic and international markets.

Utilization of IPO Proceeds

The capital raised is earmarked for strategic business expansion and strengthening of operations:

• ₹30.7 crore – Expansion of the company’s manufacturing facility
• ₹43.15 crore – Funding working capital requirements
• A portion will also be utilized for repayment of debt and other general corporate purposes

By focusing on capacity expansion and improved working capital, the company aims to enhance efficiency and support future growth in the competitive pharmaceutical sector.

Summary

The listing of Anlon Healthcare share price on September 3 was muted, with the stock opening at a 1% premium on NSE and flat on BSE. Despite strong subscription to its IPO, the debut valuation remained modest, pegging the market capitalization at ₹485 crore.

The company raised ₹121 crore through its public issue, funds that will be deployed for manufacturing expansion, working capital, debt repayment, and corporate needs. With a clear focus on APIs and pharmaceutical intermediates, Anlon Healthcare’s entry into the stock markemarks an important step in its growth journey.